Who has invested in Diasome Pharmaceuticals?

Eli Lilly and Company are named among the investors backing Diasome Pharmaceuticals.

Diasome Pharmaceuticals Funding: $90M Raised, Series C

Diasome Pharmaceuticals funding overview

Diasome Pharmaceuticals is based in Cleveland, Ohio. Diasome Pharmaceuticals has raised $90M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in December 2023. The round record for Diasome Pharmaceuticals runs through 2023; nothing later has been disclosed. Investors on record include Eli Lilly and Company.

Diasome Pharmaceuticals at a glance

Total raised: $90M
Latest round: Series C
Latest round date: December 2023
Headquarters: Cleveland, Ohio
Notable investors: Eli Lilly and Company

Frequently asked about Diasome Pharmaceuticals funding

How much has Diasome Pharmaceuticals raised?: Diasome Pharmaceuticals has raised $90M in total disclosed funding across the rounds on record.
Who has invested in Diasome Pharmaceuticals?: Eli Lilly and Company are named among the investors backing Diasome Pharmaceuticals.
What was the latest Diasome Pharmaceuticals funding round?: The most recent disclosed round is a Series C, announced in December 2023.
Where is Diasome Pharmaceuticals based?: Diasome Pharmaceuticals is based in Cleveland, Ohio.
When did Diasome Pharmaceuticals last raise?: The last disclosed Diasome Pharmaceuticals round closed in December 2023 at Series C.

We update the Diasome Pharmaceuticals record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Cleveland and their backers are listed below.

Diasome Pharmaceuticals Funding: $90M Raised, Series C

Diasome Pharmaceuticals funding overview

Diasome Pharmaceuticals at a glance

Frequently asked about Diasome Pharmaceuticals funding

Companies related to Diasome Pharmaceuticals (34)

Browse related funding lists (4)